Table 7 The detailed resistance rate (%) of Pseudomonas aeruginosa during 2022Q1 to 2023Q2
Antimicrobial | 2022Q1 (n = 50) | 2022Q2 (n = 31) | 2022Q3 (n = 64) | 2022Q4 (n = 43) | 2023Q1 (n = 55) | 2023Q2 (n = 45) |
|---|---|---|---|---|---|---|
Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | |
Amikacin (loanword) | 4 | 3.26 | 1.6 | 0 | 7.3 | 6.7 |
Voltaren, a trade name for diclofenac sodium, an antifungal agent | 14 | 6.5 | 4.7 | 11.6 | 7.3 | 6.7 |
Polymyxin B | 0 | 0 | 4.2 | 3.8 | 3 | 0 |
Ciprofloxacin | 6 | 9.7 | 17.2 | 4.7 | 9.1 | 8.9 |
Meropenem (loanword) | 8 | 3.2 | 14.1 | 4.7 | 5.5 | 4.4 |
Piperacillin (loanword) | 12.9 | 0 | 10.4 | 0 | 18.2 | 10.5 |
Piperacillin/tazobactam | 12 | 3.2 | 7.8 | 7.7 | 10.9 | 2.2 |
Gentamycin (antibiotic) | 0 | 12.9 | 14.1 | 11.9 | 3.6 | 4.4 |
Ticarcillin/baric acid | 16.1 | 9.1 | 14.6 | 0 | 18.2 | 5.3 |
Cefepime | 13 | 0 | 2.1 | 7.7 | 12.1 | 5.3 |
Cefoperazone/sulbactam | 8 | 9.7 | 4.7 | 7.7 | 5.5 | 4.4 |
Ceftazidime (pharmacology) | 8 | 6.5 | 12.5 | 4.8 | 14.5 | 17.8 |
Tobramycin (antibiotic) | 0 | 3.2 | 10.9 | 11.9 | 5.5 | 4.4 |
Imipenem (tylenol) | 13 | 0 | 14.6 | 0 | 9.1 | 10.5 |
Levofloxacin | 8 | 12.9 | 20.3 | 7.7 | 10.9 | 17.8 |